Cargando…
In silico discovery of a FOXM1 driven embryonal signaling pathway in therapy resistant neuroblastoma tumors
Chemotherapy resistance is responsible for high mortality rates in neuroblastoma. MYCN, an oncogenic driver in neuroblastoma, controls pluripotency genes including LIN28B. We hypothesized that enhanced embryonic stem cell (ESC) gene regulatory programs could mark tumors with high pluripotency capaci...
Autores principales: | Vanhauwaert, Suzanne, Decaesteker, Bieke, De Brouwer, Sara, Leonelli, Carina, Durinck, Kaat, Mestdagh, Pieter, Vandesompele, Jo, Sermon, Karen, Denecker, Geertrui, Van Neste, Christophe, Speleman, Frank, De Preter, Katleen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6269481/ https://www.ncbi.nlm.nih.gov/pubmed/30504901 http://dx.doi.org/10.1038/s41598-018-35868-5 |
Ejemplares similares
-
Publisher Correction: In silico discovery of a FOXM1 driven embryonal signaling pathway in therapy resistant neuroblastoma tumors
por: Vanhauwaert, Suzanne, et al.
Publicado: (2019) -
Early and late effects of pharmacological ALK inhibition on the neuroblastoma transcriptome
por: Claeys, Shana, et al.
Publicado: (2017) -
From DNA Copy Number Gains and Tumor Dependencies to Novel Therapeutic Targets for High-Risk Neuroblastoma
por: Decaesteker, Bieke, et al.
Publicado: (2021) -
TBX2 is a neuroblastoma core regulatory circuitry component enhancing MYCN/FOXM1 reactivation of DREAM targets
por: Decaesteker, Bieke, et al.
Publicado: (2018) -
Integrative analysis identifies lincRNAs up- and downstream of neuroblastoma driver genes
por: Rombaut, Dries, et al.
Publicado: (2019)